This week’s big news across the global nutrition and supplements industries includes ChromaDex testing of NR products, a new partnership that aims to develop probiotics for NEC and Nexira entering the GLP-1 space.
ChromaDex analysis of NR products yields ‘disappointing’ results
Only about 25% of Nicotinamide Riboside products tested were found to have 90% to 100% of the stated label claim for the vitamin B3 form, according to new testing from ChromaDex.
All the products were analyzed using a validated High Performance Liquid Chromatography (HPLC) method with a UV-Vis detector, according to ChromaDex’s white paper detailing the results.
“This study underscores the need for diligent consumer awareness in the NR marketplace,” the white paper stated. “While a small portion of NR products meet their label claims, 87% do not, with high-water-content and liposomal formats being particularly problematic. The NR dose provided in many of these products would impart no clinical benefit to the consumer. Further, some of the top-selling NR products were shown to be grossly and continuously misrepresenting the NR content in their product.”
Kirin’s subsidiary and US firm to develop probiotics for suppressing NEC
Tokyo-based Cowellnex, part of the Kirin Holdings group, is partnering with California-based Siolta Therapeutics to develop probiotics for suppressing necrotizing enterocolitis (NEC), a serious condition which Johns Hopkins Medicine refers as “the death of intestinal tissue”. It is characterized by infection and inflammation in the gut.
Cowellnex was formed last September via a joint venture between Kirin and Kyowa-Kirin. Siolta Therapeutics specializes in microbiome science and developing products for preventing or treating microbiome-related diseases among women and infants, such as pediatric atopic diseases and bacterial vaginosis in women.
“Despite improvements in neonatal care, NEC remains associated with complications and a high mortality rate, making it urgent to develop effective ways to suppress the onset of NEC and develop treatments,” Kirin said.
“This joint research will utilize Siolta’s unique research platform to develop a live bacterial formulation that suppresses the onset of NEC.”
Nexira launches two new ingredients for the weight management sector
French ingredient supplier Nexira has entered the GLP-1 space with two products for healthy weight management plus a range of products to assist with GLP-1-related side effects, including gut disturbances and additional nutritional needs.
Referred to as the Get Fit approach, the products offer a “full range of weight management solutions”, according to Leslie Lannebere, international marketing manager for health at Nexira.
The two new ingredients for weight management are Carolean, a patent-pending complex combining carob (a member of the legume family) and nopal (also known as prickly pear cactus) for appetite control, and a natural grape extract called VinOgrape, which is described as a prebiotic polyphenol concentrated in antioxidant compounds such as oligomeric procyanidins (OPC) and anthocyanins.
